ADAP — Adaptimmune Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $365.30m
- $218.36m
- $60.28m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -137 | -130 | -158 | -165 | -114 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 11.9 | 12.9 | 27.6 | 19.1 | -11.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 4.72 | 56 | 135 | -1.53 | -25 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -113 | -53.6 | 10.7 | -142 | -141 |
Capital Expenditures | -3.07 | -2.91 | -8.78 | -29.7 | -4.88 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 98 | -276 | 84.6 | 119 | 181 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 94.9 | -279 | 75.8 | 89.1 | 177 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.366 | 340 | 3.29 | 12.9 | 0.88 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -17.6 | 6.58 | 90.2 | -42.1 | 37.4 |